ReviewTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2026
From Donation to Innovation: New Blood-Derived Products.
Review in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent advances in transfusion medicine are transforming donated blood into a versatile source for a new generation of therapeutic products. This narrative review summarizes emerging innovations across plasma, red blood cells (RBCs), platelets, donor stem cells, and cord blood. Summary: Developments in plasma technology, including dried plasma, isoagglutinin-depleted universal plasma, and protein-derived products aim to enhance safety, stability, and clinical applicability. RBC innovations focus on improved preservation, engineered or artificial oxygen carriers, extracellular vesicle-based products, and strategies for producing universal blood cells. Platelet-derived products such as platelet-rich plasma, platelet lysates, and platelet extracellular vesicles are expanding applications beyond hemostasis into regenerative medicine. Advances in donor stem cell technologies offer new pathways for scalable, donor-independent production of blood cells. Additionally, cord blood (CB)-derived red cells represent a promising new product with unique biological properties. Key Message: Together, these developments illustrate a shift toward more engineered, customizable, and sustainable blood-derived therapeutics, with the potential to address clinical needs unmet by traditional transfusion components.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.